CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals ann...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SUZHOU, China, Nov. 21, 2021 /PRNewswire-AsiaNet/ -- - CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region- CStone will retain the rights to develop and commercialize an...
Authors: LATEST ASIANET NEWS RELEASES